NCT01787552 - A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 8, 2013

Primary Completion Date

April 10, 2018

Study Completion Date

April 10, 2018

Conditions

Primary MyelofibrosisThrombocytosisEssential ThrombocythemiaPolycythemia VeraMyeloproliferative DisordersBone Marrow DiseasesHematologic DiseasesBlood Coagulation DisordersBlood Platelet DisordersHemorrhagic Disorders

Interventions

DRUG

LDE225

DRUG

INC424

Trial Locations (18)

3000

Novartis Investigative Site, Leuven

4000

Novartis Investigative Site, Roskilde

4102

Novartis Investigative Site, Woolloongabba

13273

Novartis Investigative Site, Marseille

28034

Novartis Investigative Site, Madrid

39120

Novartis Investigative Site, Magdeburg

50134

Novartis Investigative Site, Florence

52074

Novartis Investigative Site, Aachen

89124

Novartis Investigative Site, Reggio Calabria

NSW

Novartis Investigative Site, Camperdown

M5G 2M9

Novartis Investigative Site, Toronto

H3T 1E2

Novartis Investigative Site, Montreal

Unknown

Novartis Investigative Site, Galway

1081 HV

Novartis Investigative Site, Amsterdam

3015 GD

Novartis Investigative Site, Rotterdam

08036

Novartis Investigative Site, Barcelona

G12 0YN

Novartis Investigative Site, Glasgow

SE1 9RT

Novartis Investigative Site, London